Spots Global Cancer Trial Database for ovarian clear cell carcinoma
Every month we try and update this database with for ovarian clear cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AMT-151 in Patients With Selected Advanced Solid Tumours | NCT05498597 | Advanced Solid ... Advanced Cancer Advanced Carcin... Ovarian Cancer Ovarian Carcino... Ovarian Epithel... Ovarian Endomet... Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial End... Endometrial Cle... Lung Adenocarci... Triple Negative... Pancreatic Duct... Malignant Pleur... Ovarian Clear C... Ovarian Clear C... Ovarian Mucinou... | AMT-151 | 18 Years - | Multitude Therapeutics Inc. | |
| Asian Multicenter Prospective Study of ctDNA Sequencing | NCT05099978 | Cervical Cancer Ovarian Clear C... Nasopharyngeal ... Ovarian Cancer Endometrial Can... Triple Negative... | NGS analysis of... | 18 Years - | National Cancer Center, Japan | |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | NCT05281471 | Platinum-resist... Platinum-refrac... Fallopian Tube ... Primary Periton... High-grade Sero... Endometrioid Ov... Ovarian Clear C... | olvimulogene na... Platinum chemot... Non-platinum ch... Bevacizumab (or... | 18 Years - | Genelux Corporation | |
| A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | NCT04104776 | Advanced Solid ... Diffuse Large B... Lymphoma, T-Cel... Mesothelioma, M... Prostatic Neopl... Endometrial Can... Ovarian Clear C... | CPI-0209 | 18 Years - | Constellation Pharmaceuticals | |
| Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma | NCT04735861 | Ovarian Clear C... | Sintilimab Bevacizumab Bio... | 18 Years - 75 Years | Tongji Hospital | |
| A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary | NCT06279104 | Ovarian Clear C... | physician's cho... immune checkpoi... | 18 Years - 75 Years | Tongji Hospital | |
| A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary | NCT06279104 | Ovarian Clear C... | physician's cho... immune checkpoi... | 18 Years - 75 Years | Tongji Hospital | |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | NCT05415098 | Nasopharyngeal ... Castrate Resist... Gastric Cancer Ovarian Clear C... Mesothelioma Sarcoma Non Hodgkin Lym... B Cell Lymphoma Epithelioid Sar... | APG-5918 | 18 Years - | Ascentage Pharma Group Inc. | |
| A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | NCT05226507 | Advanced Solid ... Ovarian Cancer Ovarian Clear C... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Endomet... ARID1A Gene Mut... | NXP800 | 18 Years - | Nuvectis Pharma, Inc. | |
| A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas | NCT03405454 | Ovarian Clear C... | durvalumab standard chemot... | 21 Years - 99 Years | National University Hospital, Singapore | |
| A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma | NCT05600998 | Ovarian Clear C... | Camrelizumab | 18 Years - 75 Years | Peking University Third Hospital | |
| A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary | NCT06279104 | Ovarian Clear C... | physician's cho... immune checkpoi... | 18 Years - 75 Years | Tongji Hospital | |
| Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium | NCT02866370 | Ovarian Clear C... Endometrial Cle... | Nintedanib Paclitaxel Pegylated Lipos... Topotecan Carboplatin Doxorubicin | 18 Years - | NHS Greater Glasgow and Clyde | |
| Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium | NCT02866370 | Ovarian Clear C... Endometrial Cle... | Nintedanib Paclitaxel Pegylated Lipos... Topotecan Carboplatin Doxorubicin | 18 Years - | NHS Greater Glasgow and Clyde | |
| Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 | NCT06065462 | Ovarian Clear C... | Dostarlimab LB-100 | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | NCT05415098 | Nasopharyngeal ... Castrate Resist... Gastric Cancer Ovarian Clear C... Mesothelioma Sarcoma Non Hodgkin Lym... B Cell Lymphoma Epithelioid Sar... | APG-5918 | 18 Years - | Ascentage Pharma Group Inc. | |
| A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary | NCT06279104 | Ovarian Clear C... | physician's cho... immune checkpoi... | 18 Years - 75 Years | Tongji Hospital | |
| A Study of ENMD-2076 in Ovarian Clear Cell Cancers | NCT01914510 | Ovarian Clear C... | ENMD-2076 | 18 Years - | University Health Network, Toronto | |
| Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer | NCT05296512 | Ovarian Clear C... Gynecologic Can... | Lenvatinib Pembrolizumab | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
